Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 analogue with 97 % amino acid homology with native glucagon-like peptide-1 and greatly protracted action. It is widely used for the treatment of type 2 diabetes mellitus, and administered by subcutaneous injection once daily. The pharmacokinetic properties of liraglutide enable 24-h exposure coverage, a requirement for 24-h glycaemic control with once-daily dosing. The mechanism of protraction relates to slowed release from the injection site, and a reduced elimination rate owing to metabolic stabilisation and reduced renal filtration. Drug exposure is largely independent of injection site, as well as age, race and ethnicity. Increasing body weight and male sex are associated with reduced concentrations, but there is substantial overlap between subgroups; therefore, dose escalation should be based on individual treatment outcome. Exposure is reduced with mild, moderate or severe renal or hepatic impairment. There are no clinically relevant changes in overall concentrations of various drugs (e.g. paracetamol, atorvastatin, griseofulvin, digoxin, lisinopril and oral combination contraceptives) when co-administered with liraglutide. Pharmacodynamic studies show multiple beneficial actions with liraglutide, including improved fasting and postprandial glycaemic control (mediated by increased insulin and reduced glucagon levels and minor delays in gastric emptying), reduced appetite and energy intake, and effects on postprandial lipid profiles. The counter-regulatory hormone response to hypoglycaemia is largely unaltered. The effects of liraglutide on insulin and glucagon secretion are glucose dependent, and hence the risk of hypoglycaemia is low. The pharmacokinetic and pharmacodynamic properties of liraglutide make it an important treatment option for many patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Primary structure of liraglutide. Compared with native GLP-1 (7–37), liraglutide has lysine replaced with arginine in position 34, and the lysine at position 26 is acylated on its ε-amino group with the γ-carboxyl group of N-palmitoyl-l-glutamic acid. GLP-1 glucagon-like peptide-1. Republished with permission of © Dove Medical Press Ltd. from Deacon. Vasc Health Risk Manag. 2009;5:199–211 [21]; permission conveyed through Copyright Clearance Center, Inc](https://figures.cochat.ai/paper-figures/c2eb76f98855443e8c48117058c2da8f/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-1.jpg)
![Fig. 2 Mean concentration profiles of liraglutide following steady-state doses of 0.6 mg (n = 9), 1.2 mg (n = 9) and 1.8 mg (n = 8) in healthy male Chinese subjects. With permission of © John Wiley & Sons, Inc. from Jiang et al. J Clin Pharmacol. 2011;51:1620–7 [42]](https://figures.cochat.ai/paper-figures/30d2b29ba4374c538da71ae99f6176f8/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-2.jpg)
![Fig. 3 Model-derived steady-state concentration profile of liraglutide (20 μg/kg) dosed once daily. With permission of © John Wiley & Sons, Inc.; adapted from Watson et al. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol. 2010;50:886–94 [46]](https://figures.cochat.ai/paper-figures/45e09538af3940d0b7122b25a9e38153/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-3.jpg)
![Fig. 4 Dose-proportionality plot of liraglutide exposure at steady state. Open circles represent individual study subjects. Squares represent mean values at each dose in healthy male Chinese subjects. The line represents the regression line from a linear model with logarithmic transformed AUC and dose under the assumption of dose proportionality (r 2 = 0.96). AUC area under the concentration–time curve in a dosing interval (24 h). Data from Jiang et al. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. J Clin Pharmacol 2011;51:1620–7 [42] © John Wiley and Sons, analysis results from data on file](https://figures.cochat.ai/paper-figures/ddf261cb8e78429c8a1df714b4a57f05/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-4.jpg)
![Fig. 5 Forest plot of covariate effects on liraglutide dose-normalised exposure (AUC) relative to a reference subject (Chinese female individual aged <65 years and with a body weight of 67 kg). Data are mean (90 % CI). Vertical dotted lines indicate bioequivalence limits of 0.8–1.25. The column to the right provides numerical values of geometric mean relative exposures with 90 % CIs obtained by likelihood profiling. AUC area under the concentration–time curve, CI confidence interval, y years. Reprinted from Ingwersen et al. Diabetes Res Clin Pract. 2015;108:113–9 [35], with permission from © Elsevier Ireland Ltd](https://figures.cochat.ai/paper-figures/9ae31b3760294c56846f9721efb6b2c0/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-5.jpg)
![Fig. 6 Liraglutide exposure (AUC and C max) following liraglutide 0.75 mg in subjects with renal or hepatic impairment relative to healthy controls. Data are mean exposures (with 90 % CI) for each group (n = 5–7 per group) relative to healthy subjects. Broken vertical lines illustrate the no-effect boundaries (0.70–1.43) used in the assessment. AUC area under the concentration–time curve, CI confidence interval, C max maximum concentration. Renal impairment data from Jacobsen et al. Br J Clin Pharmacol. 2009;68:898–905 [41]. Hepatic impairment data from Flint et al. Br J Clin Pharmacol. 2010;70:807–14 [38]](https://figures.cochat.ai/paper-figures/a0810b5790e44bf798f1584788234420/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-6.jpg)
![Fig. 7 Effects of liraglutide 1.8 mg on the exposure of selected co-administered drugs. Data are mean relative exposures (with 90 % CI) when co-administered with liraglutide vs. co-administration with placebo. The trials consisted of healthy subjects (atorvastatin n = 42, griseofulvin n = 27, lisinopril n = 38, digoxin n = 26, ethinylestradiol/levonorgestrel n = 21) and subjects with type 2 diabetes (acetaminophen n = 18 and insulin detemir n = 32). Broken vertical lines illustrate the no-effect boundaries (0.80–1.25) used in the assessment. Ethinylestradiol and levonorgestrel were administered as a combination product. AUC area under the concentration–time curve, C max maximum concentration. Data from Malm-Erjefält et al. Mol Pharm. 2015; doi: 10.1021/acs.molpharmaceut.5b00278 [44]; Jacobsen et al. J Clin Pharmacol. 2011;51:1696–703 [53]; Kapitza et al. Adv Ther. 2011;28:650–60 [54]; Morrow et al. Diabetes Obes Metab. 2011;13:75–80 [56]](https://figures.cochat.ai/paper-figures/37caac17c046495f89192b8208f70a03/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-7.jpg)
![Fig. 8 Mean postprandial glucose profiles during a standardised meal test performed in 18 subjects with type 2 diabetes dosed with liraglutide or placebo. During each 3-week treatment period, the liraglutide/placebo dose was escalated weekly in 0.6-mg increments from 0.6 to 1.2 mg and 1.8 mg. Postprandial glucose measures were performed at steady-state liraglutide 0.6-mg (red squares), 1.2-mg (blue triangles), and 1.8-mg (green circles) doses, and for placebo (matched grey lines). © With kind permission from Springer Science + Business Media: Advances in Therapy, The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. 2011;28:213–26, Flint et al., Fig. 1 [61]](https://figures.cochat.ai/paper-figures/5594525b0f3f4263b57258969e95bbd6/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-8.jpg)
![Fig. 9 Mean insulin profiles following glucose bolus injection (inserted), during a hyperglycaemic clamp and following an arginine stimulation test in 13 subjects with type 2 diabetes treated for 9 days with liraglutide 6 µg/kg (~0.55 mg) or placebo. Glucose bolus (first phase): 0–17 min; hyperglycaemic clamp (second phase): 90–120 min; arginine stimulation test (maximum insulin secretion): 120–150 min. © American Diabetes Association. Diabetes, American Diabetes Association, 2004. Copyright and all rights reserved. Material from this publication has been adapted with the permission of the American Diabetes Association from Degn et al. Diabetes. 2004;53:1187–94 [66]](https://figures.cochat.ai/paper-figures/a712653b361e4c7f8711556001fe9bdb/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-9.jpg)
![Fig. 10 Glucose-dependent stimulation of insulin secretion in subjects with type 2 diabetes treated with liraglutide. Relationship between insulin secretion rate (ISR) and plasma glucose levels during graded glucose infusion in subjects with type 2 diabetes (n = 10) receiving liraglutide 7.5 µg/kg (~0.66 mg; blue squares) or placebo (grey circles). Values from healthy controls (n = 10) who did not receive liraglutide (black triangles) are also shown. ISR was derived by deconvolution of C-peptide concentrations. Data are mean ± standard error; n = 10 for each group. © American Diabetes Association. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. From Chang et al. Diabetes. 2003;52:1786–91 [59]](https://figures.cochat.ai/paper-figures/812592d9e79648288b7bf0978e489da9/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-10.jpg)
![Fig. 11 Exposure–response relationship of liraglutide effects on HbA1c in subjects with type 2 diabetes. Figure shows percentage change from baseline in HbA1c following 14 weeks of treatment in a phase II dose-finding study (grey circles) and following 12 weeks of treatment in a phase III study (blue squares). The exposure–response relationships were evaluated by dividing liraglutide concentration values from each trial into quartiles. Exposures are trough concentrations for the phase II trial and model-derived mean concentrations for the phase III trial. HbA 1c glycated haemoglobin, SE standard error. With permission of © John Wiley & Sons, Inc.; adapted from Ingwersen et al. Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment. J Clin Pharmacol. 2012;52:1815–23 [33]](https://figures.cochat.ai/paper-figures/b7e333da49824b5a99bb3c107e08b4c5/liraglutide-in-type-2-diabetes-mellitus-clinical-pharmacokinetics-and-figure-11.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the treatment of T2DM, liraglutide helps lower blood sugar levels by increasing insulin production and reducing glucose production by the liver.81”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“In any case, it has been suggested that the effect of liraglutide on gastric emptying decreases over time, owing to tolerance development as a result of continuous activation of the GLP-1 receptor [79].”
BackgroundNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“However, although intravenous infusion of native GLP-1 can normalise plasma glucose levels in patients with type 2 diabetes [22, 23], it is not a practical option for exogenous therapy.”
BackgroundGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 8×
“Based on data from a phase III study in the USA, as well as a dose-finding phase II study, the mean change from baseline in HbA1c at 12–14 weeks was plotted for various doses of liraglutide (up to 1.8 mg and including placebo) given as monotherapy [33].”
BackgroundMethodInfluentialGhoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Research works printed but not linked: 1
- International Diabetes Federation. Diabetes atlas: sixth edition. 2014 update. http://www.idf.org/diabetesatlas . Accessed 24 Sep 2015.
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The acylation also promotes multimeric formation, which decelerates diffusion from the site of injection [893].”
BackgroundGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“81,107,109 Tanzeum was discontinued by GlaxoSmithKline (GSK) in 2017, primarily due to economic factors.”
BackgroundEmerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“liraglutide’s pharmacokinetic properties allow for 24 h glycemic management with a single dose, owing to metabolic stabilization and reduced renal filtration that slow down release from the injection site and eliminate the medication more slowly [84].”
BackgroundRecent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Metadata
- Authors
- Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Ingwersen, Steen H.
- ORCID
- Flint, Anne
- Venue
- Clinical Pharmacokinetics
- Published
- 2015-11-23
- Volume
- 55
- Issue
- 6
- Pages
- 657-672
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC4875959
- OpenAlex
- W2174832318
- Cited by
- 217
- References
- 78
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 43 · 2023: 34 · 2022: 20 · 2021: 14 · 2020: 18 · 2019: 20 · 2018: 11 · 2017: 4 · 2016: 7 · 2015: 1
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, type 2 diabetes, glucagon-like peptide-1 analogues, pharmacokinetics, pharmacodynamics, glycemic control, insulin secretion, glucagon secretion, gastric emptying, hypoglycemia, renal dysfunction, liver dysfunction, drug interactions, dose escalation, subcutaneous injection
- MeSH terms
- Liraglutide, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Interactions, Glucagon, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Lipids, Sex Factors, Liver Failure, Area Under Curve, Renal Insufficiency, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. https://app.cochat.ai/papers/10.1007/s40262-015-0343-6
- The paper
- Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016). Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-015-0343-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.